NEW DRUG INFORMATION ● Rybrevant ™ (amivantamab-vmjw): The U.S. Food and Drug Administration (FDA) has granted the accelerated approval of Rybrevant (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or aſter platinum-based chemotherapy. Rybrevant is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations, which are the third most prevalent activating EGFR mutation. Patients newly diagnosed with metastatic NSCLC with EGFR exon 20 insertion mutations have a median overall survival (OS) of 16.2 months. Rybrevant was approved based on a Phase 1 study, CHRYSALIS, that evaluated Rybrevant as monotherapy as well as in combination with lazertinib. Rybrevant’s overall response rate (ORR) was 40% with 3.7% of patients having a complete response and 36% of patients achieving partial responses. 1 Rybrevant launch and pricing are pending. ● Camcevi ™ (leuprolide mesylate): The FDA approved Foresee Pharmaceuticals’ Camcevi 42mg, a ready-to-use six-month subcutaneous depot formulation of leuprolide mesylate, as a treatment of advanced prostate cancer. The FDA approval was based on a single arm, Phase 3 study that demonstrated treatment with Camcevi injection every six months was effective, safe and well tolerated. The primary efficacy end point was the percentage of subjects with suppression of serum testosterone (≤50 ng/dl) by day 28 and from day 28 to day 336 in the intent-to-treat population. The primary efficacy endpoint was successfully achieved in 97% of subjects, with mean testosterone concentration suppressed below castrate levels to 17.6 ng/dL on day 28. 2 Camcevi launch and pricing are pending. ● Truseltiq ™ (infigratinib): The FDA has approved BridgeBioPharma’s Truseltiq under the accelerated approval program for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement. Truseltiq is an orally administered, ATP-competitive, tyrosine kinase inhibitor of FGFR. CCA affects approximately 20,000 people in the United States and Europe each year and has a median five-year survival rate of 9%. The approval of Truseltiq was based on a Phase 2 clinical study where patients received 125 mg of Truseltiq once daily for 21 days of 28-day cycles. Of these patients, 99% had Stage IV CCA and all patients had received at least one prior line of systemic therapy. Truseltiq demonstrated an ORR of 23% and a median duration of response (DoR) of five months. Truseltiq has launched with a list price of $21,500 per month which is about 5% lower than Incyte’s Pemazyre, which has a similar indication. 3 While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner. Critical updates in an ever changing environment Specialty Pipeline MONTHLY UPDATE June 2021
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
NEW DRUG INFORMATION ● Rybrevant™ (amivantamab-vmjw): The U.S. Food and Drug Administration (FDA) has granted the
accelerated approval of Rybrevant (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. Rybrevant is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations, which are the third most prevalent activating EGFR mutation. Patients newly diagnosed with metastatic NSCLC with EGFR exon 20 insertion mutations have a median overall survival (OS) of 16.2 months. Rybrevant was approved based on a Phase 1 study, CHRYSALIS, that evaluated Rybrevant as monotherapy as well as in combination with lazertinib. Rybrevant’s overall response rate (ORR) was 40% with 3.7% of patients having a complete response and 36% of patients achieving partial responses.1 Rybrevant launch and pricing are pending.
● Camcevi™ (leuprolide mesylate): The FDA approved Foresee Pharmaceuticals’ Camcevi 42mg, a ready-to-use six-month subcutaneous depot formulation of leuprolide mesylate, as a treatment of advanced prostate cancer. The FDA approval was based on a single arm, Phase 3 study that demonstrated treatment with Camcevi injection every six months was effective, safe and well tolerated. The primary efficacy end point was the percentage of subjects with suppression of serum testosterone (≤50 ng/dl) by day 28 and from day 28 to day 336 in the intent-to-treat population. The primary efficacy endpoint was successfully achieved in 97% of subjects, with mean testosterone concentration suppressed below castrate levels to 17.6 ng/dL on day 28.2 Camcevi launch and pricing are pending.
● Truseltiq™ (infigratinib): The FDA has approved BridgeBioPharma’s Truseltiq under the accelerated approval program for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement. Truseltiq is an orally administered, ATP-competitive, tyrosine kinase inhibitor of FGFR. CCA affects approximately 20,000 people in the United States and Europe each year and has a median five-year survival rate of 9%. The approval of Truseltiq was based on a Phase 2 clinical study where patients received 125 mg of Truseltiq once daily for 21 days of 28-day cycles. Of these patients, 99% had Stage IV CCA and all patients had received at least one prior line of systemic therapy. Truseltiq demonstrated an ORR of 23% and a median duration of response (DoR) of five months. Truseltiq has launched with a list price of $21,500 per month which is about 5% lower than Incyte’s Pemazyre, which has a similar indication.3
While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner.
Critical updates in an ever changing environment
Specialty Pipeline MONTHLY UPDATE
June 2021
Specialty Pipeline Monthly Update: June 2021 Page 2
● Lumakras™ (sotorasib): Amgen’s Lumakras has received accelerated approval by the FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. Approximately 13% of NSCLC patients have KRAS G12C mutations. Lumakras’ approval was based on the Phase 1/2 CODEBREAK 100, which demonstrated that previously treated patients with metastatic KRAS G12C-mutant NSCLC had a 36% ORR and an 81% of patients achieving disease control for more than three months.4 Lumakras has a median duration of response of 10 months. Lumakras has launched with a list price of about $17,900 per month or an average wholesale price (AWP) of $21,480 per 30-day supply (240-tab bottle). Amgen is currently assessing Lumakras in other solid tumors that have a similar KRAS mutation.5
● Ryplazim® (plasminogen, human-tvmh): The FDA approved Liminal BioSciences’ Ryplazim for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia). Patients with congenital plasminogen deficiency experience an accumulation of fibrin growths or lesions on mucosal surfaces throughout the body. Many cases are first diagnosed in the pediatric population, and if left untreated, disease manifestations may be organ-compromising. Ryplazim’s BLA resubmission was based on a Phase 2/3, open-label study evaluating the safety and efficacy of Ryplazim in 15 patients, which demonstrated 100% of the patients enrolled met both primary efficacy endpoints of the clinical study.6 Primary endpoint was a surrogate target of increase in blood plasma concentration level of plasminogen. Additionally, all patients who had active visible lesions had complete healing of lesions, a 100% response rate, within one week. Ryplazim launch and price are pending.
● Aduhelm® (aducanumab-avwa): The FDA granted accelerated approval to Biogen’s Aduhelm for the treatment of Alzheimer’s disease. The controversial approval was based on reduction in amyloid beta plaques observed in patients treated with Aduhelm. In November 2020, The Peripheral and Central Nervous System Drugs Advisory Committee overwhelmingly voted no on several counts regarding the efficacy and evidence supporting the use of aducanumab in AD. Based on clinical trials, EMERGE and ENGAGE, eight experts voted no, aducanumab did not provide “strong evidence” in treating patients with Alzheimer’s, one expert voted yes, and two voted uncertain.7 In May 2021, the Institute for Clinical and Economic Review released a draft report estimating that the drug should cost between $2,560 to $8,290 per year, and noted that “the evidence is insufficient to conclude that the clinical benefits of aducanumab outweigh its harms or, indeed, that it reduces progression” of Alzheimer’s disease.8 The wholesale acquisition price (WAC) price of Aduhelm, which requires an infusion once every four weeks, is $4,312 per infusion, or an average of $56,000 annually based on a 74 kg person. Biogen plans to launch Aduhelm in the next few weeks.
● Epclusa® pellets (sofosbuvir/velpatasvir): The FDA has approved an oral pellet formulation of Gilead Sciences’ hepatitis C drug Epclusa for use in young children who cannot swallow tablets as young as age three. Epclusa was originally approved by the FDA for adults in 2016 and then expanded their indication to include children six years of age and up. Epclusa pellets were approved based on one open-label Phase 2 trial that evaluated the efficacy and safety. Epclusa pellets demonstrated a sustained virologic response at a rate of 83% among all patients and 88% in patients with HCV genotype 1, 50% in patients with HCV genotype 2 and 100% in patients with HCV genotypes 3 and 4.9 The pellets are available in two dosages to accommodate children who weigh more or less than 17 kg. Each dose of the oral pellets comes in an individual packet that needs to be shaken, cut or torn open, and sprinkled onto food or directly into the mouths of people aged six years and older. Epclusa pellets launch and price are pending.
Specialty Pipeline Monthly Update: June 2021 Page 3
● StrataGraft® (bioengineered skin tissue): The FDA approved Mallinckrodt’s StrataGraft for the treatment of adult patients with thermal burns containing intact dermal elements (remaining deep skin layers) for which surgical intervention is clinically indicated, also referred to as deep, partial thickness burns. StrataGraft is produced from two kinds of human skin cells, keratinocytes and dermal fibroblasts, that are grown together to make a bi-layered construct. StrataGraft is for topical application, placed onto the burn by a health care provider. Over time, the patient’s skin cells should grow to replace the skin cells lost as a result of the burn. Treatment with StrataGraft can help avoid or decrease the amount of healthy skin that is needed for grafting. StrataGraft was approved based on the Phase 3 STRATA2016 clinical trial that demonstrated 96% of the StrataGraft-treated burn sites across all participants did not require autografting.10 StrataGraft launch and price are pending.
NEW INDICATIONS ● Zeposia® (ozanimod): The FDA expanded the indication of Bristol-Myers Squibb’s Zeposia to include
treatment of adults with moderately to severely active ulcerative colitis (UC).
● Ultomiris® (ravulizumab-cwvz): The FDA expanded the indication of Alexion’s Ultomiris to include the treatment of pediatric patients with paroxysmal nocturnal hemoglobinuria (PNH).
● Ayvakit® (avapritinib): The FDA approved Blueprint Medicines Corp’s Ayvakit to include a new indication for treatment of adults with advanced systemic mastocytosis (SM).
MARCH NEWS ● “The FDA said that its Cardiovascular and Renal Drugs Advisory Committee of outside experts will
convene on July 15 to review the safety and efficacy of FibroGen’s potential treatment for anemia in chronic kidney disease. The drug, known as roxadustat, has been hit with cardiovascular safety questions recently as the company had to double back and inform the FDA of some post-hoc changes. The announcement that an advisory committee would be necessary, which came in early March, also was a surprise. Wall Street biotech analysts and others like the Institute for Clinical and Economic Review (ICER) remain mixed on the drug overall. ICER said it determined that the evidence is insufficient to know whether roxadustat provides a net health benefit over an ESA, but at a placeholder price of $6,500 per year, roxadustat may be cost-saving in the dialysis independent population.”10
● “As Capitol Hill begins to wake up to the financial and scientific mess behind the FDA’s approval of Biogen’s new controversial Alzheimer’s drug Aduhelm, nonprofit watchdog Public Citizen is now calling for the top three FDA officials who are responsible to be removed from their positions. In a letter to HHS Secretary Xavier Becerra on Wednesday, the group highlighted the “litany of flaws” in the FDA’s approval of the new drug, including the “unprecedented, inappropriately close” collaboration between the FDA and Biogen in the analysis of key trial data, basing approval on an unvalidated surrogate endpoint, not following the advice of its expert advisory committee (three members of which have since resigned), and the wide label that the agency granted. In addition to requesting that Becerra seek the resignations or the removal of acting FDA commissioner Janet Woodcock, CDER Director Patrizia Cavazzoni, and Office of Neuroscience director Billy Dunn because of the approval, Public Citizen also wants Becerra to direct the next FDA commissioner to consider withdrawing the Aduhelm approval.”11
Specialty Pipeline Monthly Update: June 2021 Page 4
SPECIALTY NEW PRODUCT APPROVALS IN THE PAST TWELVE MONTHS
GENERIC NAME BRAND NAME MANUFACTURER INDICATION(S)ROUTE OF ADMINISTRATION
MONTH APPROVED
bioengineered skin tissue StrataGraft™ Mallinckrodt Deep partial-thickness thermal burns
Topical June 2021
sofosbuvir/velpatasvir Epclusa® pellets Gilead Hepatitis C Oral June 2021
aducanumab-avwa Aduhelm® Biogen Alzheimer’s disease IV June 2021
plasminogen (human-tvmh) Ryplazim® Prometic Life Sciences Inc
calcium, magnesium, potassium, and sodium oxybates
Xywav™ Jazz Pharmaceuticals
Excessive daytime sleepiness Oral July 2020
Specialty Pipeline Monthly Update: June 2021 Page 5
NEW INDICATIONS FOR APPROVED SPECIALTY PRODUCTS
GENERIC NAME BRAND NAME MANUFACTURER NEW INDICATION(S) DATE APPROVED
ravulizumab-cwvz Ultomiris® Alexion Pediatric patients with paroxysmal nocturnal hemoglobinuria (PNH)
June 2021
ozanimod Zeposia® Bristol-Myers Squibb
Treatment of adults with moderatly to severely active ulcerative colitis (UC)
May 2021
omalizumab Xolair® Genentech New prefilled syringe for treatment of persistent asthma and chronic idiopathic urticaria
April 2021
risankizumab-rzaa Skyrizi® AbbVie New autoinjector and a prefilled syringe with needle stock prevention for treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
April 2021
treprostinil Tyvaso® United Therapeutics Corp
Pulmonary hypertension associated with interstitial lung disease to improve exercise ability
March 2021
tocilizumab Actemra® Genentech Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease
March 2021
adalimumab Humira® AbbVie Moderately to severely active ulcerative colitis in adults and pediatric patients five years of age and older
February 2021
romiplostim Nplate® Amgen Increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, or HSARS)
January 2021
carglumic acid Carbaglu® Recordati Rare Diseases
Adjunctive therapy to standard of care for treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA)
January 2021
ivacaftor Kalydeco® Vertex Diagnostics
Expanded population cystic fibrosis patients with additional rare CFTR mutations
December 2020
anakinra Kineret® Sobi Treatment of patients with Deficiency of IL-1 Receptor Antagonist (DIRA)
December 2020
ocrelizumab Ocrevus® Genentech Relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS)
December 2020
tezacaftor and ivacaftor Symdeko® Vertical Pharmaceutical
Expanded population for the combination regimen of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector and the CFTR potentiator for treatment of cystic fibrosis patient
December 2020
belimumab Benlysta® GlaxoSmithKline Lupus nephritis December 2020
rilonacept Arcalyst® Regeneron and Kiniksa
Deficiency of the interleukin-1 receptor antagonist (DIRA)
December 2020
pitolisant Wakix® Harmony Biosciences
Cataplexy in adults with narcolepsy October 2020
ravulizumab-cwvz Ultomiris® Alexion Higher concentrations formula for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)
October 2020
C1 Esterase Inhibitor Subcutaneous (Human)
Haegarda® CSL Behring Routine prophylaxis of hereditary angioedema attacks in patients six years of age and older
September 2020
golimumab Simponi Aria® Johnson & Johnson (Janssen)
Patients two years of age and older for the treatment of active psoriatic arthritis (PsA) or active polyarticular juvenile idiopathic arthritis (pJIA)
September 2020
ivacaftor Kalydeco® Vertex Expanded population (ages four months to less than six months old) for the combination regimen of the cystic fibrosis
September 2020
continued
Specialty Pipeline Monthly Update: June 2021 Page 6
NEW INDICATIONS FOR APPROVED SPECIALTY PRODUCTS (continued)
GENERIC NAME BRAND NAME MANUFACTURER NEW INDICATION(S) DATE APPROVED
tofacitinib Xeljanz® Pfizer Pediatric patients two years and older with juvenile idiopathic arthritis (pcJIA)
September 2020
mepolizumab Nucala® GlaxoSmithKline Pediatric patient 12 years and older with hypereosinophilic syndrome (HES)
September 2020
dolutegravir and lamivudine Dovato® ViiV Healthcare Switch treatment for HIV-1 infection August 2020
cannabidiol Epidiolex® GW Pharmaceuticals PLC
Seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older
July 2020
ONCOLOGY PRODUCT APPROVALS IN THE PAST TWELVE MONTHS
GENERIC NAME BRAND NAME MANUFACTURER INDICATION(S)ROUTE OF ADMINISTRATION
DATE APPROVED
sotorasib Lumakras® Amgen Certain forms of lung cancer Oral May 2021
infigratinib Truseltiq® QED Therapeutics (BridgeBio)
Certain forms of cholangiocarcinoma
Oral May 2021
leuprolide mesylate 50 mg depot
Camcevi® 42mg Foresee Pharmaceuticals
Palliative treatment of advanced prostate cancer
Injectable suspension
May 2021
amivantamab-vmjw Rybrevant™ Johnson & Johnson
Certain forms of non-small cell lung cancer
IV May 2021
dostarlimab-gxly Jemperli™ GlaxoSmithKline (Tesaro) and AnaptysBio
melphalan flufenamide Pepaxto™ Oncopeptides Certain forms of relapsed refractory multiple myeloma (RRMM)
IV February 2021
trilaciclib Cosela™ G1 Therapeutics Myelopresservation IV February 2021
umbralisib Ukoniq™ TG Therapeutics Marginal zone lymphoma (MZL) Oral February 2021
tepotinib Tepmetko® EMD Serono Certain forms of metastatic non-small cell lung cancer (NSCLC)
Oral February 2021
relugolix Orgovyx™ Myovant Prostate cancer Oral December 2020
margetuximab-cmkb Margenza™ MacroGenics Breast cancer IV December 2020
naxitamab-gqgk Danyelza™ Y-mAbs Relapsed or refractory high-risk neuroblastoma
IV November 2020
pralsetinib Gavreto™ Blueprint RET fusion-positive non-small cell lung cancer (NSCLC)
Oral September 2020
azacitidine Onureg™ Bristol-Myers Squibb
Acute myeloid leukemia (AML) Oral September 2020
cedazuridine and decitabine, C-DEC
Inqovi™ Astex Pharmaceuticals (Otsuka)
Myelodysplastic syndrome (MDS)
Oral August 2020
tafasitamab-cxix Monjuvi™ MorphoSys AG Relapsed/refractory diffuse large B cell lymphoma
IV August 2020
continued
Specialty Pipeline Monthly Update: June 2021 Page 7
GENERIC NAME BRAND NAME MANUFACTURER INDICATION(S)ROUTE OF ADMINISTRATION
DATE APPROVED
belantamab mafodotin-blmf Blenrep™ GlaxoSmithKline Multiple myeloma IV August 2020
lurbinectedin Zepzelca™ PharmaMar and Jazz Pharmaceuticals
Small cell lung cancer (SCLC) IV August 2020
decitabine and cedazuridine Inqovi™ Astex Pharmaceuticals
Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)
Oral July 2020
ONCOLOGY PRODUCT APPROVALS IN THE PAST TWELVE MONTHS (continued)
NEW INDICATIONS FOR APPROVED ONCOLOGY DRUGS
GENERIC NAME BRAND NAME MANUFACTURER NEW INDICATION DATE APPROVED
avapritinib Ayvakit® Blueprint Medicines Corp
Adults with advanced systemic mastocytosis (SM) June 2021
pembrolizumab Keytruda® Merck Certain combination for first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
May 2021
nivolumab Opdivo® Bristol-Myers Squibb
Adjuvant treatment of patients with resected esophageal or gastroesophageal junction (GEJ) cancer after neoadjuvant chemoradiation therapy (CRT)
May 2021
nivolumab Opdivo® Bristol-Myers Squibb
Certain forms of advanced or metastatic gastric cancer, gastroesophageal junction cancer (GEJC) or esophageal adenocarcinoma (EAC)
May 2021
lorlatinib Lorbrena® Pfizer Treatment of previously untreated advanced ALK-positive non-small cell lung cancer (NSCLC)
April 2021
sacituzumab govitecan-hziy Trodelvy® Gilead Sciences Triple-negative breast cancer that has spread to other parts of the body
April 2021
nivolumab Opdivo® Bristol-Myers Squibb
Initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma
April 2021
pembrolizumab Keytruda® Merck Certain forms of locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction (GEJ)
March 2021
axicabtagene ciloleucel Yescarta® Kite Pharm Relapsed or refractory follicular lymphoma and marginal zone lymphoma after two or more prior lines of systemic therapy
March 2021
cytarabine and daunorubicin Vyxeos® Jazz Pharmaceuticals
Certain forms of acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
March 2021
sacituzumab govitecan-hziy Trodelvy® Gilead Sciences Adult patients with locally advanced or metastatic urothelial cancer (UC)
March 2021
isatuximab-irfc Sarclisa® Sanofi PS Multiple myeloma who have received at least one prior therapy
March 2021
cemiplimab-rwlc Libtayo® Regeneron Monotherapy for treatment of first line locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression
February 2021
cemiplimab-rwlc Libtayo® Regeneron Treatment of locally advanced or metastatic basal cell carcinoma (BCC)
February 2021
continued
Specialty Pipeline Monthly Update: June 2021 Page 8
GENERIC NAME BRAND NAME MANUFACTURER NEW INDICATION DATE APPROVED
pralsetinib Gavreto® Blueprint medicines
Treatment of patients with advanced or metastatic RET mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancers.
February 2021
darolutamide Nubeqa® Bayer Pharmaceutical
Non-metastatic castration-dependent prostate cancer
January 2021
daratumumab and hyaluronidase-fihj
Darzalex Faspro® Janssen Biotech and Genmab
Light chain (AL) amyloidosis January 2021
fam-trastuzumab deruxtecan-nxki
Enhertu® Daiichi Pharmaceutical
Patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
January 2021
cabozantinib Cabometyx® Exelixis In combination with the immuno-oncologic nivolumab (Bristol-Myers Squibb's Opdivo) for first-line treatment of advanced renal cell carcinoma (RCC)
January 2021
nivolumab Opdivo® Bristol-Myers Squibb
In combination with cabozantinib (Exelixis' Cabometyx) for first-line treatment of advanced renal cell carcinoma (RCC)
January 2021
crizotinib Xalkori® Pfizer Pediatric patients with certain forms of relapsed or refractory systemic anaplastic large cell lymphoma
January 2021
selinexor Xpovio® Karyopharm Treatment of patients with multiple myeloma after at least one prior line of therapy
December 2020
osimertinib Tagrisso® AstraZeneca Adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent
December 2020
ponatinib Iclusig® Takeda Pharmaceuticals
Chronic-phase (CP) chronic myeloid leukemia (CML) with resistance
December 2020
durvalumab Imfinzi® AstraZeneca New four-week, fixed-dose regimen for the PD-L1 inhibitor immuno-oncologic, consistent with approved dosing in extensive-stage small cell lung cancer (ES-SCLC), for Imfinzi's approved indications in urothelial cancer and non-small cell lung cancer (NSCLC)
November 2020
pembrolizumab Keytruda® Merck In combination with chemotherapy for treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10)
November 2020
pembrolizumab Keytruda® Merck Monotherapy for treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL)
October 2020
nivolumab and ipilimumab Opdivo® and Yervoy®
Bristol-Myers Squibb
First line treatment for malignant pleural mesothelioma
October 2020
daratumumab Darzalex® Johnson & Johnson (Janssen)
New combination for treatment of relapsed or refractory multiple myeloma
August 2020
carfilzomib Kyprolis® Amgen New combination for treatment of relapsed or refractory multiple myeloma
August 2020
atezolizumab Tecentriq® Genentech (Roche)
New combination for treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma
July 2020
guselkumab Tremfya® Johnson & Johnson
Adults with active psoriatic arthritis (PsA) July 2020
NEW INDICATIONS FOR APPROVED ONCOLOGY DRUGS (continued)
Specialty Pipeline Monthly Update: June 2021 Page 9
BIOSIMILAR PRODUCT APPROVALS IN THE PAST TWELVE MONTHS
GENERIC NAME BRAND NAMEREFERENCE PRODUCT MANUFACTURER INDICATION(S)
ROUTE OF ADMINISTRATION
MONTH APPROVED
rituximab-arrx Riabni™ Rituxan® Amgen Oncology IV December 2020
adalimumab-fkjp Hulio™ Humira® Mylan Autoimmune SC July 2020
SPECIALTY PIPELINE
GENERIC NAME BRAND NAME MANUFACTURER INDICATION(S)ROUTE OF ADMINISTRATION
ANTICIPATED APPROVAL DATE*
eflapegrastim Rolontis™ Spectrum Pharmaceuticals and Hanmi Pharmaceutical
Chemotherapy-induced neutropenia SC Delayed- 2021
CPP-1X/sul (eflornithine and sulindac)
N/A Cancer Prevention Pharmaceuticals
Familial adenomatous polyposis (FAP)
Oral Delayed- 2021
tanezumab N/A Pfizer And Lilly Osteoarthritis SC 2Q2021